Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb confirmatory study of vebreltinib in MET exon 14-mutated advanced or metastatic non-small cell lung cancer
CTR20232228Phase 3Active
- Sponsor
- Beijing Purunao Biotechnology
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Purunao Biotechnology. Started Oct 2023; status: active.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20232228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232228.